Nabiqasim Industries (Pvt) Ltd.,
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Karachi · Pakistan
Pakistan-based pharmaceutical manufacturer producing branded generic formulations with domestic and international operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Nabiqasim Industries (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 5th Floor, Commerce Centre, Hasrat Mohani Road, Karachi, Pakistan
- Website
- nabiqasim.com ↗
- Phone
- +92 21 111 742 762
- info@nabiqasim.com
- Official contact
- Contact page ↗
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Nabiqasim Industries (Pvt) Ltd., is priced against the market
313 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Reline | Sertraline | 100 mg | Tablet | 30's | 089318 | PKR 2,908.03 | PKR 96.93/tablet | 🔒 Pharma Pro |
| Reline | Sertraline | 100 mg | Tablet | 20's | 089318 | PKR 1,938.70 | PKR 96.94/tablet | 🔒 Pharma Pro |
| Rivab | Ribavirin | 200 mg | Capsule | 10's | 083984 | PKR 475.63 | PKR 47.56/capsule | 🔒 Pharma Pro |
| Rivab | Ribavirin | 400 mg | Tablet | 10's | 095985 | PKR 174.74 | PKR 17.47/tablet | 🔒 Pharma Pro |
| Romycin | Azithromycin | 250 mg | Capsule | 6's | 024331 | PKR 372.74 | PKR 62.12/capsule | 🔒 Pharma Pro |
| Romycin | Azithromycin | 250 mg | Tablet | 12's | 055583 | PKR 615.60 | PKR 51.30/tablet | 🔒 Pharma Pro |
| Romycin | Azithromycin | 250 mg | Tablet | 6s | 055583 | PKR 314.08 | PKR 52.35/tablet | 🔒 Pharma Pro |
| Romycin | Azithromycin | 500 mg | Tablet | 6s | 055584 | PKR 575.81 | PKR 95.97/tablet | 🔒 Pharma Pro |
| Romycin | Azithromycin | 500 mg | Tablet | 3s | 055584 | PKR 288.95 | PKR 96.32/tablet | 🔒 Pharma Pro |
| Romycin | Azithromycin | 200 mg/5 mL | Suspension | 30ml | 061448 | PKR 663.86 | PKR 22.13/mL | 🔒 Pharma Pro |
| Romycin | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 061448 | PKR 338.70 | PKR 22.58/mL | 🔒 Pharma Pro |
| Scabex | Permethrin | 5% | Cream | 30g | 085593 | PKR 124.51 | PKR 4.15/g | 🔒 Pharma Pro |
| Scabex | Permethrin | 50 mg/mL (5%) | Lotion | 60ml | 097333 | PKR 138.06 | PKR 2.30/mL | 🔒 Pharma Pro |
| Silderm | Silver sulfadiazine | 1% w/w | Cream | 15g | 090774 | PKR 87.37 | PKR 5.82/g | 🔒 Pharma Pro |
| Silderm | Silver sulfadiazine | 10 mg/g | Cream | 50g | 090774 | PKR 256.27 | PKR 5.13/g | 🔒 Pharma Pro |
| Silderm | Silver sulfadiazine | 10 mg/g | Cream | 20g | 090774 | PKR 116.48 | PKR 5.82/g | 🔒 Pharma Pro |
| Silderm | Silver sulfadiazine | 10 mg/g | Cream | 250g | 090774 | PKR 485.37 | PKR 1.94/g | 🔒 Pharma Pro |
| Silderm | Silver sulfadiazine | 10 mg/g | Cream | 25g | 090774 | PKR 145.61 | PKR 5.82/g | 🔒 Pharma Pro |
| Simva | Simvastatin | 20 mg | Tablet | 10's | 027204 | PKR 557.95 | PKR 55.80/tablet | 🔒 Pharma Pro |
| Simva | Simvastatin | 10 mg | Tablet | 20's | 027207 | PKR 546.93 | PKR 27.35/tablet | 🔒 Pharma Pro |
| Simva | Simvastatin | 10 mg | Tablet | 10's | 027207 | PKR 279.05 | PKR 27.91/tablet | 🔒 Pharma Pro |
| Simva | Simvastatin | 20 mg | Tablet | 20's | 027208 | PKR 1,093.59 | PKR 54.68/tablet | 🔒 Pharma Pro |
| Simva | Simvastatin | 40 mg | Tablet | 10's | 044195 | PKR 857.11 | PKR 85.71/tablet | 🔒 Pharma Pro |
| Solbovir | Sofosbuvir | 400 mg | Tablet | 28’s | 108620 | PKR 10,126.88 | PKR 361.67/tablet | 🔒 Pharma Pro |
| Suzera Tablet 50mgRegistry verified | Suzetrigine | — | — | — | 135207Official source ↗ | No indexed price | — | — |
| Talavil Tablet 10mgRegistry verified | Tadalafil | — | — | — | 134976Official source ↗ | No indexed price | — | — |
| Talavil Tablet 2.5mgRegistry verified | Tadalafil | — | — | — | 134975Official source ↗ | No indexed price | — | — |
| Talavil Tablet 20mgRegistry verified | Tadalafil | — | — | — | 134974Official source ↗ | No indexed price | — | — |
| Talavil Tablet 5mgRegistry verified | Tadalafil | — | — | — | 134973Official source ↗ | No indexed price | — | — |
| Tazicillin | Piperacillin + tazobactam | 4 g + 0.5 g | Powder for injection | 1's | 120010 | PKR 1,596.45 | PKR 1,596.45/vial/unit | 🔒 Pharma Pro |
| Tazicillin | Piperacillin + tazobactam | 2 g + 0.25 g | Powder for injection | 1's | 120011 | PKR 702.19 | PKR 702.19/vial/unit | 🔒 Pharma Pro |
| Tecmiso | Misoprostol | 100 mcg | Tablet | 10's | 076132 | PKR 125.64 | PKR 12.56/tablet | 🔒 Pharma Pro |
| Tecmiso | Misoprostol | 200 mcg | Tablet | 10's | 076133 | PKR 209.39 | PKR 20.94/tablet | 🔒 Pharma Pro |
| Tranmax | Tranexamic acid | 500 mg/5 mL | Injection | 5ml x 10's | 091229 | PKR 1,650.24 | PKR 33.00/mL | 🔒 Pharma Pro |
| Tranmax | Tranexamic acid | 250 mg/5 mL | Injection | 5ml x 10’s | 110289 | PKR 647.00 | PKR 12.94/mL | 🔒 Pharma Pro |
| Triject | Ceftriaxone | 250 mg | IV injection | 1's | 058372 | PKR 208.60 | PKR 208.60/vial/unit | 🔒 Pharma Pro |
| Triject | Ceftriaxone | 500 mg | Injection | 1's | 058373 | PKR 351.11 | PKR 351.11/vial/unit | 🔒 Pharma Pro |
| Triject | Ceftriaxone | 1 g | Injection | 1's | 058374 | PKR 662.97 | PKR 662.97/vial/unit | 🔒 Pharma Pro |
| Triject | Ceftriaxone | 250 mg | IM injection | 1's | 058375 | PKR 208.60 | PKR 208.60/vial/unit | 🔒 Pharma Pro |
| Triject | Ceftriaxone | 500 mg | Injection | 1's | 058376 | PKR 351.11 | PKR 351.11/vial/unit | 🔒 Pharma Pro |
| Triject | Ceftriaxone | 1 g | Injection | 1's | 058377 | PKR 662.97 | PKR 662.97/vial/unit | 🔒 Pharma Pro |
| Uriside | Furosemide | 20 mg | Tablet | 100's | 101395 | PKR 190.66 | PKR 1.91/tablet | 🔒 Pharma Pro |
| Uriside | Furosemide | 40 mg | Tablet | 100's | 101396 | PKR 321.02 | PKR 3.21/tablet | 🔒 Pharma Pro |
| Valset | Valproic acid | 250 mg/5 mL | Syrup | 60ml | 053137 | PKR 97.08 | PKR 1.62/mL | 🔒 Pharma Pro |
| Valset | Valproic acid | 250 mg/5 mL | Syrup | 120ml | 053137 | PKR 184.66 | PKR 1.54/mL | 🔒 Pharma Pro |
| Valset Tabs | Valproic acid | 500 mg | Tablet | 100's | 053134 | PKR 970.73 | PKR 9.71/tablet | 🔒 Pharma Pro |
| Valset Tabs | Valproic acid | 250 mg | Tablet | 100's | 053142 | PKR 485.36 | PKR 4.85/tablet | 🔒 Pharma Pro |
| Vanbact | Vancomycin | 500 mg | IV injection | 1's | 070682 | PKR 1,465.71 | PKR 1,465.71/vial/unit | 🔒 Pharma Pro |
| Vanbact | Vancomycin | 1 g | IV injection | 1's | 070683 | PKR 2,366.09 | PKR 2,366.09/vial/unit | No comparator |
| Vaspro | Hydralazine | 25 mg | Tablet | 20's | 083939 | PKR 105.08 | PKR 5.25/tablet | 🔒 Pharma Pro |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.